Skip to main content

Table 1 Demographics, clinical features and biomarkers

From: Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease

 

HC (n = 48)

PD (n = 46)

p-values

Female

32 (66.6 %)

18 (39 %)

0.85

Male

16 (33.3 %)

28 (61 %)

 

Age

63 (57–67)

64 (57–71)

0.7969

Disease years

-

4 (2–8.3)

-

H&Y Stage

-

2 (2–2.5)

N.A

UPDRS- III

-

23 (15.3–27)

N.A

MMSE

29 (29–30)

29 (28–30)

0.0479

t-α-syn (ng/ml)

1.6 (1.3–2.2)

1.3 (1.2–1.6)

<0.0001

p-S129-α-syn (pg/ml)

222 (180.5–275)

261 (206.8–296.3)

<0.001

o-α-syn (pg/ml)

57 (36–106.5)

116 (76–170)

<0.0001

p-S129/t-α-syn %

13.7 (9.2–18.5)

18.6 (15.7–23.3)

<0.0001

o-/t-α-syn %

3.5 (2.3–6.2)

8.9 (5.2–12.2)

<0.0001

t-tau (pg/ml)

229 (162–271.5)

190 (157.8–274.3)

0.1710

p-tau (pg/ml)

41.5 (29.3–50.3)

41.1 ± 16

0.5965

Aβ42 (pg/ml)

995.5 (877.5–1153)

966.5 (794–1077)

0.6745

  1. Median, interquartile ranges and p-values of Mann-Whitney U test continuous variables, Count (percentage) for categorical ones
  2. Abbreviations: HC healthy controls, PD Parkinson’s disease, H&Y Hoehn and Yahr, UPDRS- III Unified Parkinson’s Disease Rating Scale-Part-III, MMSE mini-mental state examination, t-α-syn total α-synuclein, p-S129-α-syn phosphorylated Ser 129 α-synuclein, o-α-syn oligomeric α-synuclein, t-tau total-tau, p-tau phosphyorylated-tau, Aβ42 amyloid beta-42
Back to article page

Molecular Neurodegeneration

ISSN: 1750-1326